New Cleveland Clinic research reveals that up to 5% of Americans—approximately 17 million people—carry genetic mutations or "variants" linked to increased cancer susceptibility, regardless of risk ...

Human semen not only accumulates genetic mutations with age; as the percentage of sperm carrying potentially serious mutations increases, so does the risk of developing diseases in offspring. This is ...

A study completed at the University of Helsinki and the Folkhälsan Research Center analysed 390 parent–offspring trios. Trio denotes a design where the genomes of the puppy and both parents are ...

A CRISPR system detects rare cancer mutations in blood with single-nucleotide precision, outperforming ddPCR through engineered RNA guides and isothermal amplification. (Nanowerk Spotlight) Hidden ...

Human eggs appear to be protected against a certain type of age-related mutation. In a small study, researchers found no signs that mutations accumulate in the mitochondrial DNA of human egg cells as ...

A newly discovered genetic mutation unique to humans may help explain why we are significantly more vulnerable to cancer than our closest evolutionary relatives. Researchers at the University of ...

Researchers at Weill Cornell Medicine report that a rare gene mutation that delays Alzheimer’s disease does so by damping inflammatory signaling in brain-resident immune cells in a preclinical study.

Childhood cancers are often considered genetically simple, containing few mutations. However, this notion has been challenged in a new study that found an unexpectedly high number of mutations in a ...

Gear-obsessed editors choose every product we review. We may earn commission if you buy from a link. Why Trust Us? Without 8 or 9 hours of sleep, most of us end up staggering around like zombies. But ...

A newly identified mutation helps super-sleepers get by on just four to six hours of shut-eye per night, while the rest of us need around eight hours. Researchers described the SIK3-N783Y mutation in ...

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering ...